PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34368808-11	2021	Secondary objective was to evaluate the effects of metformin on the expression of CSC markers by measuring relative mRNA levels of CD133, OCT4 and NANOG by RT-PCR and immunohistochemistry.	Metformin	51-60	Nanog homeobox	Homo sapiens	147-152	
34368808-16	2021	Comparison of markers of CCSC results showed that expression of CD133, OCT4 and NANOG expression were decreased following metformin.	Metformin	122-131	Nanog homeobox	Homo sapiens	80-85	
32208194-3	2020	Here, we attempt to find out the effect of metformin on cancer stem cell marker CD44 and stemness related transcription factors including OCT4, SOX2, NANOG, c-Myc and KLF4.	Metformin	43-52	Nanog homeobox	Homo sapiens	150-155	
32208194-7	2020	RESULTS: Metformin showed downregulation in the gene expressions of stemness related transcription factors OCT4, SOX2, NANOG, c-Myc, and KLF4 in a dose-dependent as well as time-dependent manner.	Metformin	9-18	Nanog homeobox	Homo sapiens	119-124	
30621095-7	2019	Treatment with metformin resulted in a dose-dependent induction of the stem cell genes CD44, BMI-1, OCT-4, and NANOG.	Metformin	15-24	Nanog homeobox	Homo sapiens	111-116	
26939902-0	2016	Metformin and AICAR regulate NANOG expression via the JNK pathway in HepG2 cells independently of AMPK.	Metformin	0-9	Nanog homeobox	Homo sapiens	29-34	
26939902-5	2016	In this study, we used the HepG2 cell line and found that metformin/AICAR downregulated NANOG expression with decreased cell viability and enhanced chemosensitivity to 5-fluorouracil (5-FU).	Metformin	58-67	Nanog homeobox	Homo sapiens	88-93	
26939902-6	2016	Moreover, metformin/AICAR inhibited c-Jun N-terminal kinase (JNK) activity, and blockade of either the JNK MAPK pathway or knockdown of JNK1 gene expression reduced NANOG levels.	Metformin	10-19	Nanog homeobox	Homo sapiens	165-170	
26939902-7	2016	The upregulation of NANOG and phospho-JNK by basic fibroblast growth factor (bFGF) was abrogated by metformin/AICAR.	Metformin	100-109	Nanog homeobox	Homo sapiens	20-25	
26939902-8	2016	Additionally, although transient upregulation of NANOG within 2 h of treatment with metformin/AICAR was concordant with both JNK and AMPK activation, increased NANOG expression with activation of JNK was also observed following AMPK inhibition with compound C. Taken together, our data suggest that metformin/AICAR regulate NANOG expression via the JNK MAPK pathway in HepG2 cells independently of AMPK, and that this JNK/NANOG signaling pathway may offer new therapeutic strategies for the treatment of HCC.	Metformin	84-93	Nanog homeobox	Homo sapiens	49-54	
26939902-8	2016	Additionally, although transient upregulation of NANOG within 2 h of treatment with metformin/AICAR was concordant with both JNK and AMPK activation, increased NANOG expression with activation of JNK was also observed following AMPK inhibition with compound C. Taken together, our data suggest that metformin/AICAR regulate NANOG expression via the JNK MAPK pathway in HepG2 cells independently of AMPK, and that this JNK/NANOG signaling pathway may offer new therapeutic strategies for the treatment of HCC.	Metformin	84-93	Nanog homeobox	Homo sapiens	160-165	
26939902-8	2016	Additionally, although transient upregulation of NANOG within 2 h of treatment with metformin/AICAR was concordant with both JNK and AMPK activation, increased NANOG expression with activation of JNK was also observed following AMPK inhibition with compound C. Taken together, our data suggest that metformin/AICAR regulate NANOG expression via the JNK MAPK pathway in HepG2 cells independently of AMPK, and that this JNK/NANOG signaling pathway may offer new therapeutic strategies for the treatment of HCC.	Metformin	84-93	Nanog homeobox	Homo sapiens	160-165	
26939902-8	2016	Additionally, although transient upregulation of NANOG within 2 h of treatment with metformin/AICAR was concordant with both JNK and AMPK activation, increased NANOG expression with activation of JNK was also observed following AMPK inhibition with compound C. Taken together, our data suggest that metformin/AICAR regulate NANOG expression via the JNK MAPK pathway in HepG2 cells independently of AMPK, and that this JNK/NANOG signaling pathway may offer new therapeutic strategies for the treatment of HCC.	Metformin	84-93	Nanog homeobox	Homo sapiens	160-165	
26939902-8	2016	Additionally, although transient upregulation of NANOG within 2 h of treatment with metformin/AICAR was concordant with both JNK and AMPK activation, increased NANOG expression with activation of JNK was also observed following AMPK inhibition with compound C. Taken together, our data suggest that metformin/AICAR regulate NANOG expression via the JNK MAPK pathway in HepG2 cells independently of AMPK, and that this JNK/NANOG signaling pathway may offer new therapeutic strategies for the treatment of HCC.	Metformin	299-308	Nanog homeobox	Homo sapiens	49-54	
25056111-5	2014	Low-dose metformin or SN-38 increases FOXO3 nuclear localization as well as the amount of DNA damage markers and downregulates the expression of a cancer-stemness marker CD44 and other stemness markers, including Nanog, Oct-4, and c-Myc, in these cancer cells.	Metformin	9-18	Nanog homeobox	Homo sapiens	213-218	
22086681-5	2012	Metformin also decreased the expression of CSC markers,CD44, EpCAM,EZH2, Notch-1, Nanog and Oct4, and caused reexpression of miRNAs (let-7a,let-7b, miR-26a, miR-101, miR-200b, and miR-200c) that are typically lost in pancreatic cancer and especially in pancreatospheres.	Metformin	0-9	Nanog homeobox	Homo sapiens	82-87